Neurology News | Medical XPRT

Creative Proteomics Accelerates Life Science Research Through Mass Spectrometry Platform

Creative Proteomics, experienced proteomics, metabolomics, and bioinformatics services supplier, has been well equipped with advanced technologies to meet the increasing needs of researchers and scientists in their proteomics and metabolomics related researches. In the past few years, the technology of mass spectrometry has been greatly developed and their applications broadened. Based on more ...

Aug. 17, 2021

By Creative Proteomics

Avery Biomedical Devices’ Nextgen Diaphragm Pacing Transmitter, Spirit, Earns FDA Approval – Now Available

Avery Biomedical Devices (Commack, NY), the global leader in high reliability diaphragm pacemakers, announced that its new diaphragm pacemaker transmitter, Spirit, has earned FDA approval and is now being offered to patients using its pacing system. This NextGen transmitter features a light-weight compact design with easy-to-use touch controls and offers precision-enhancing digital ...

Aug. 13, 2021

By Avery Biomedical Devices, Inc.

Second Genome Presents Preclinical Data Demonstrating the Effects of Microbial-Derived Metabolites in Autism Spectrum Disorder

Second Genome, a biotechnology company that leverages its proprietary platform sg-4sight to discover and develop precision therapies and biomarkers based on novel microbial genetic insights, presented data from the largest analysis of microbiome function in Autism Spectrum Disorder (ASD), as well as preclinical activity of microbially-derived metabolites predicted to be reduced in ASD, during an ...

Aug. 10, 2021

By Second Genome Therapeutics

Flat Medical announced FDA 510(k) clearance of EpiFaith, the Epidural Safety Solution

Flat Medical Co., Ltd., the medtech company specializing in clinical safety solutions, announced it received 510(k) clearance from the U.S. Food and Drug Administration for its EpiFaith® syringe to deliver safe epidural locating solution. Based on the LOR technique, the EpiFaith® syringe is a physician-centered safeguard for epidural analgesia, which is indicated for painless labor, ...

Aug. 7, 2021

By Flat Medical

Neuropathix, Inc. Announces Publication of PCT Patent Application for the Treatment of Radiation Dermatitis and Other Skin Disorders

Neuropathix, Inc. (“Neuropathix” or the “Company”) (OTCQB:NPTX), a socially responsible pain management life sciences company, announced today the publication of the global Patent Cooperation Treaty (PCT) Patent under Publication No. WO/2021/097351 “Functionalized 1,3-Benzene Diols and Their Method of Use for the Treatment of Radiation Dermatitis and Other Skin ...

Jul. 20, 2021

By Neuropathix, Inc.

BlueRock Therapeutics Receives FDA Fast Track Designation for DA01 in the Treatment of Advanced Parkinson`s Disease

BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly owned subsidiary of Bayer AG, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for DA01 for advanced Parkinson’s disease (PD). DA01, BlueRock’s pluripotent stem cell-derived dopaminergic neuron therapy, is under evaluation in a Phase 1 study. The FDA’s ...

Jul. 19, 2021

By BlueRock Therapeutics

Merck and INBRAIN Neuroelectronics Collaborate to Develop the Next Generation of Bioelectronic Therapies

Innovation Center project of Merck collaborates to develop smart neuro-modulation for targeted treatment of chronic diseases. Joint development agreement represents a promising step towards a highly selective and efficient next generation of bioelectronic therapies powered by graphene. INBRAIN Neuroelectronics, a company at the intersection of medtech, deeptech and digital health ...

Jul. 8, 2021

By Inbrain Neuroelectronics

RepliCel Applies for Manufacturing Approval for its Collagen and Tissue Regeneration Cell Therapies

RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP) (FRA:P6P2) (“RepliCel” or the “Company”), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce it has submitted its application to Japan’s Ministry of Health, Labour, and Welfare (MHLW) for approval to manufacture the Company’s RCT-01 cell therapy for ...

Jul. 7, 2021

By RepliCel Life Sciences

BlueRock Therapeutics Announces First Patient Dosed with DA01 in Phase 1 Study in Patients with Advanced Parkinson`s Disease

BlueRock Therapeutics, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, announced today the dose administration for the first patient in a Phase 1 (Ph1), open-label study of pluripotent stem cell-derived dopaminergic neurons in patients with advanced Parkinson’s disease (PD). The purpose of the Ph1 clinical trial is to evaluate the safety, tolerability, ...

Jun. 8, 2021

By BlueRock Therapeutics

MagForce AG Supports World Brain Tumor Day and Informs about Various Patient Events to Raise Awareness for One of the Deadliest Oncological Indications

MagForce AG (Frankfurt, Scale, Xetra: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, offering the NanoTherm Therapy System for the treatment of brain tumors, supports World Brain Tumor Day on June 8th, 2021 and informs about various virtual patient events to raise awareness for this devastating disease. “Though rare compared to ...

Jun. 7, 2021

By MagForce AG

Senti Bio and BlueRock Therapeutics Enter Collaboration to Develop Gene Circuit-Engineered Cell Therapies for Regenerative Medicine

BlueRock Therapeutics LP, a leading engineered cell therapy company and a wholly-owned and independently operated subsidiary of Bayer AG, and Senti Biosciences, Inc. (Senti Bio), a leading gene circuit company, today announced a collaboration and option agreement to apply Senti Bio’s gene circuit technology to the development of BlueRock’s next-generation engineered cell ...

May 26, 2021

By BlueRock Therapeutics

BlueRock Therapeutics, FUJIFILM Cellular Dynamics, and Opsis Therapeutics Enter into a Strategic R&D Alliance to Discover and Develop Cell Therapies for Eye Diseases

BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, FUJIFILM Cellular Dynamics, Inc. a leading global developer and manufacturer of human induced pluripotent stem (iPS) cell technologies, and Opsis Therapeutics, LLC, a joint venture of FUJIFILM Cellular Dynamics (FCDI) and David Gamm, M.D., Ph.D., co-founder, focusing on developing cell ...

May 17, 2021

By BlueRock Therapeutics

DiscGenics Completes Patient Enrollment in Japanese Clinical Study of Cell Therapy for Disc Degeneration as US Study Achieves One-Year Follow-up Milestone

DiscGenics, Inc., a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced that it has completed enrollment in its Japanese safety study of IDCT, an allogeneic, injectable Discogenic Cell therapy for lumbar disc degeneration, a major cause of ...

Apr. 27, 2021

By DiscGenics, Inc.

Creative Proteomics Provides HPLC-tMS Analysis Service for Metabolomics Profiling

With years of experience in offering professional and high-quality products for academic use and pharmaceutical industries, Creative Proteomics announces HPLC-tMS analysis service for metabolomics profiling. Metabolomics is an omics method to analyze all metabolites of a certain biological component or cell quantitatively and qualitatively under a specific physiological or pathological condition. ...

Apr. 27, 2021

By Creative Proteomics

MagForce Announces Additional Supportive Data from Stage 2a of its Pivotal U.S. Single-Arm Study for the Focal Ablation of Intermediate Risk Prostate Cancer with the NanoTherm Therapy System

Further analysis of the Stage 2a results confirm positive initial findings published in February of this year - treatment-related side effects remained minimal and tolerable with the streamlined procedure Ablation-analysis showed well-defined ablation and cell death in the area of the nanoparticle deposit, with minimum tissue damage outside 2 to 4 mm from the deposit edge Despite ongoing ...

Apr. 26, 2021

By MagForce AG

Axial Therapeutics to Present at Virtual Jefferies Microbiome-based Therapeutics Summit

Axial Therapeutics Inc., a clinical-stage biopharmaceutical company dedicated to the development of gut-targeted, small molecule therapeutics for neurological conditions and oncology, today announced that A. Stewart Campbell, Ph.D., chief executive officer, will present an overview of the company and take part in one-on-one meetings with institutional investors at the Jefferies Microbiome-based ...

Apr. 15, 2021

By Axial Therapeutics Inc.

Aspect Biosystems And Jsr Corporation Enter Collaboration To Develop Bioprinted Vascularized Tissues For Regenerative Medicine

Aspect Biosystems, a privately held biotechnology company pioneering the development of bioprinted therapeutics, is pleased to announce a new joint development program with JSR Corporation, a global leader in advanced materials innovation. This collaboration builds on the existing partnership between the two companies and will see the combining of Aspect’s proprietary microfluidic 3D ...

Mar. 30, 2021

By Aspect Biosystems Ltd.

Dicerna’s GalXC-Plus™ RNAi Technology Delivers Target Knockdown Across CNS and to Specific CNS Cell Types in Preclinical Studies

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced new data from preclinical studies of its GalXC-Plus™ RNAi technology demonstrating its potential to deliver deep and sustained messenger RNA (mRNA) knockdown against prespecified gene ...

Mar. 30, 2021

By Dicerna Pharmaceuticals, Inc.

bit.bio CEO Dr Mark Kotter speaking about challenging biology at the TEDxCambridgeUniversity ‘Untangling networks’ event

On Saturday 20 March 2021, bit.bio CEO and founder Mark Kotter was a speaker at the TEDxCambridgeUniversity ‘Untangling networks’ event. Dr Kotter was speaking about his work as a neurosurgeon, stem cell biologist and an entrepreneur. Many of the conditions he faces as a doctor, whether they are cancers, genetic or degenerative conditions, need more than a scalpel and screws or ...

Mar. 26, 2021

By bit.bio

BrainScope Launches Next-Gen Medical Device: First and only FDA-cleared system for true point-of-care assessment of both concussion and brain bleeds now includes Concussion Index

BrainScope today announced the availability of its third groundbreaking FDA-cleared algorithm on the BrainScope device. The Concussion Index is the first physiological marker of concussive injury that aids clinicians in the objective assessment of patients at baseline, point of injury, and through recovery. The Concussion Index adds to the suite of FDA cleared algorithms already available on the ...

Mar. 23, 2021

By BrainScope